Nanxin pharmaceutical has done it!

As the country with the largest population in the world, China's huge population scale has brought the demand of medical and health market At the same time, with the improvement of people's living standard, the enhancement of health care awareness and the development of new medical technology, the national medical treatment rate has been increasing, which has brought prosperity to the medical market Nanxin pharmaceutical, which is on the science and technology innovation board this time, has made great achievements in the use of influenza drugs, but the capital market is profit-making Whether Nanxin pharmaceutical can be popular in the market still needs rational analysis Innovative medicine or market development direction: Nanxin pharmaceutical is an innovative pharmaceutical enterprise focusing on the R & D, production and marketing of chemical drugs, dedicated to the R & D and industrialization of new drugs and special drugs for major and sudden diseases, so as to better meet the clinical drug demand and serve the "healthy China" strategy The domestic demand for medicine keeps stable growth, and the chemical pharmaceutical industry, as the largest sub industry of the pharmaceutical industry, has been playing an important role The main business income of China's chemical preparation manufacturing enterprises increased year by year from 2006 to 2016, with an overall growth rate of 18.48% The growth rate reached 28.45% in 2008 Although the growth rate dropped from 2012 to 2014, it was still higher than 10% In 2016, the main business income of chemical preparation manufacturing enterprises was 753.47 billion yuan, with a year-on-year growth rate of 10.54% At the same time, the total profits of Chinese chemical pharmaceutical manufacturing enterprises also increased at the same time From 2006 to 2016, the compound growth rate of the total profits of Chinese chemical pharmaceutical manufacturing enterprises reached 23.51% The growth rate of total profit is higher than that of main business income It can be seen that China's chemical preparation manufacturing enterprises still maintain a positive and good profit trend Source of growth of main business income of China's chemical preparation manufacturing enterprises from 2006 to 2016: from the perspective of technology, in the domestic chemical preparation industry, 90% of generic drugs and modified drugs are available, and the types and quantity of independently developed drugs are seriously insufficient However, innovative drugs usually have the characteristics of unique efficacy and small side effects Once they are put on the market, they will produce huge social and economic benefits However, the process of new drug R & D and regulatory approval is long and expensive, and the process from R & D to final listing is uncertain, which requires a lot of industrial technical knowledge and strong financial strength The research and development of an innovative drug in China needs to go through pre clinical research, clinical research application, phase I, II, III clinical trials, new drug registration application and approval process of the State Drug Administration, which generally takes more than 10 years and requires a large amount of research and development costs For a long time, China's pharmaceutical enterprises mainly produce generic drugs On the contrary, in the United States, where the pharmaceutical industry is relatively mature, generic drugs also occupy an absolute advantage in the number of drugs However, from the perspective of sales volume, the relatively small number of new drugs supports the main drug market, which is the opposite of the situation in China In general, the field of innovative drugs in China is still in its early stage, and there is still a great room for growth Nanxin Pharmaceutical Co., Ltd is expected to open up the market In recent years, Nanxin Pharmaceutical Co., Ltd has a small number of national class 1.1 innovative drugs approved for listing After several years of industrialization, it has been recognized by the market At present, Nanxin Pharmaceutical Co., Ltd has a strong competitive advantage in the field of anti influenza drugs Panamivir sodium chloride injection product of Nanxin pharmaceutical is named "Liwei ®", which shows strong antiviral activity in vivo and in vitro, and is suitable for influenza A or B The main route of administration of existing neuraminidase inhibitors for influenza virus is oral administration and inhalation Source: prospectus (sorted by Dao Kechuang) Paramivir is the first all-age intravenous drug for influenza treatment in China, which has the advantages of quick effect and long duration At the same time, it has a good therapeutic effect on patients with loss of will, to a certain extent, it makes up for the shortcomings of other drugs, and it is effective for patients with severe influenza, patients who cannot accept inhalation or oral administration, and other neuraminidase inhibitors Patients with poor or drug resistance provide new treatment options At the same time, it has good advantages in efficacy, applicable population, adverse reactions and price As the main recommended anti influenza drugs of neuraminidase inhibitors in the influenza diagnosis and treatment program 2019 edition, the sales of oseltamivir, zanamivir and palamivir in China in recent years are as follows: according to the data statistics of minenet, the sales of oseltamivir, zanamivir and palamivir in public hospitals at city and county level in 2018 are 232 respectively, 9.1 million yuan, 1.33 million yuan and 191.93 million yuan Source: the sales expenses of Prospectus have increased sharply, and the product competitiveness needs to be improved in 2016-2018 The revenue of Nanxin pharmaceutical is 278 million, 348 million and 701 million respectively, up 24.82% and 101.58% year-on-year respectively; the net profit attributable to the parent is 15 million, 27 million and 54 million respectively, up 85.87% and 97.15% year-on-year respectively However, in 2016, 2017, 2018 and January June 2019, the company's sales expenses were 54.5412 million yuan, 122.5866 million yuan, 41.7993 million yuan and 275.7555 million yuan, respectively As the highest proportion of expenses, the growth of sales expenses is mainly due to the substantial growth of academic education expenses From 2016 to 2018, the company's academic education fees were 32.53 million, 101.77 million and 38.204 million, respectively The main purpose of increasing the academic education fees is to introduce the efficacy, publicize the treatment scheme and gain market trust In order to publicize its new drug, Nanxin pharmaceutical has made great efforts On the other hand, in terms of revenue structure by product, generic drugs account for a relatively high proportion of the main business revenue of Nanxin pharmaceutical From 2016 to the first half of 2019, the sales revenue of the company's generic products was RMB 254 million, RMB 277 million, RMB 549 million and RMB 257 million respectively, accounting for 91.51%, 79.79%, 78.32% and 56.47% of the main business revenue respectively But on the other hand, the proportion of this part is gradually declining, the market of innovative drugs is slowly expanding, and it is still necessary to track this business in the future To sum up, Nanxin pharmaceutical does focus on innovative drugs in the prospectus I will do the same If there is no innovative drug, can Nanxin pharmaceutical go to the science and technology innovation board or another way On the whole, innovative drugs have a good market If the drug effect meets the expectation, there will be a good market share However, in order to accelerate the promotion of innovative drugs, a series of measures will bring side effects, which will be a hidden danger This paper only represents the author's personal point of view, not the Tao science and technology innovation platform The opinions in this article are only for communication and sharing, and do not constitute any investment suggestions for investors Operate accordingly at your own risk Penicillin